Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 907-913

  Yazici, Yusuf ^a   Krasnokutsky, Svetlana ^a   Barnes, Jaime P ^b   Hines, Patricia L ^b   Wang, Jason ^b   Rosenblatt, Lisa ^b  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dose escalation; Rheumatoid arthritis; Switching; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; DATA BASE; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; COHORT ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG USE; FACTUAL DATABASE; HEALTH INSURANCE; HEALTH SERVICE; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION REVIEW; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449088331     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080592     Document Type: Article

References (20)

1. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-12.
2. Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004;63 Suppl 2:ii32-ii39.
3. Kamal KM, Madhavan SS, Hornsby JA, Miller LA, Kavookjian J, Scott V. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 2006;73:718-24.
4. Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 2004;63:607-8.
5. Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
6. Gomez-Reino JJ, Carmona L, and the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
7. Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
8. Iannone F, Trotta F, Montecucco C, et al., GISEA (Gruppo Italiano per lo Studio delle Early Arthritis). Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Arthritis Rheum 2007;66:249-52.
9. Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy [letter]. Ann Rheum Dis 2004;63:896.
10. Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006;65:257-60.
11. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-9.
12. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
13. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
14. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
15. van der Heijde D, Klareskog L, Rodriguez-Valverde R, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
16. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
17. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9 Suppl:S136-43.
18. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
19. Brocq O, Roux CH, Albert C, et al. TNF-a antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74:148-54.
20. Geborek P, Crnkic M, Petersson IF, Saxne T for the South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.